H2AX and cancer: Interestingly, we have found that H2AFX scored as one of the strongest hits in loss-of-function CRISPR-Cas9 screens performed in distinct human cancer cell lines treated with the ATMi AZD0156 (Supplementary Fig. 5d), as also previously found.